1. At a Glance – The “Speciality” Company That Forgot Its Specialty
There was a time when Chemcon was the cool kid in the Indian chemical space — monopoly vibes (only HMDS manufacturer in India), global leadership (largest CMIC player), and customers straight out of pharma royalty. Fast forward to today… and the story feels like a Bollywood sequel nobody asked for.
Revenue is stuck, margins are moody, profits are shrinking, and the stock has been behaving like it just went through a breakup. PAT dropped 42% YoY in Q3 FY26. ROE is chilling at a modest 5%. Sales growth over 5 years? Negative. And yet — promoters hold a solid 74.5% stake like nothing is wrong.
So what’s happening here?
Is this a temporary slowdown due to global chemical cycles… or is this a classic case of “great product, poor execution”?
Why is a company with global leadership in niche chemicals delivering local kirana-store level returns?
And most importantly…
Is this a turnaround brewing quietly… or a slow chemical reaction going wrong?
Let’s investigate.
2. Introduction – From Monopoly to Mediocre?
Chemcon Speciality Chemicals started as a niche chemical manufacturer — and not just any niche. We’re talking high-value intermediates used in pharma and oil drilling, where entry barriers are supposed to be high.
The company built its reputation on:
- HMDS (only manufacturer in India)
- CMIC (largest manufacturer globally)
- Bromides (oil drilling chemicals)
Basically, it had:
- Monopoly
- Export exposure
- Pharma tailwinds
Sounds like a dream combo, right?
But then reality entered like a surprise tax notice.
According to management commentary:
- Demand has been weak
- Pricing pressure continues
- Chinese dumping is affecting global markets
- Oil drilling slowdown impacting bromides
So now the company is stuck between:
- Weak pharma demand
- Volatile oil sector
- Global pricing pressure
And here’s the twist…
Despite all this, revenue hasn’t collapsed — it’s just flat and uninspiring.
Which raises a question:
If your products are “speciality,” why are your margins behaving like commodities?
3. Business Model – WTF Do They Even Do?
Let’s simplify Chemcon’s business.
Two Segments:
1. Organic Chemicals (78%)
- HMDS
- CMIC
- Bromobenzene
- 2-Bromo
Used in:
2. Inorganic Chemicals (16%)
Used in:
Translation for Lazy Investors:
They make chemicals that:
- Help pharma companies manufacture drugs
- Help oil companies drill holes in the earth
Basically:
- One segment depends on human disease
- Other depends on oil demand
Nice diversification… but also double risk.
Key Strength:
- Monopoly in HMDS (India)
- Global leadership in CMIC
- Strong client list (Hetero, Aurobindo, Laurus)
Key Problem:
Customer concentration:
- Top 5 = 30% revenue
- Top 10 = 45% revenue
So if 2–3 clients sneeze, Chemcon catches cold.
Expansion Drama:
- New plants (P10 & P11) delayed to H2 FY26
- Acquisition of Shivam Petrochem
